Understanding ATTR cardiac amyloidosis — the under-diagnosed heart condition now treatable with TTR stabilizers, gene silencers, and an emerging CRISPR cure — diagnosis, medications, clinical trials, and practical resources organized by where you are in your journey.
This guide is not medical advice. It is an educational research summary written in plain language, drawn from published medical literature, major clinical trials, and official guidelines. Every important decision must be made together with the patient’s medical team. Nothing here replaces those conversations. The purpose of this guide is to help patients and families walk into those conversations better prepared. This content does not create a doctor-patient relationship. Trouvera’s guides are produced using AI-assisted research synthesis with human editorial review; they are not written by treating physicians. Laws regarding medical information vary by jurisdiction; consult a local licensed professional for advice specific to your situation.
Standard care first. The information in this guide is intended to support — never replace — the care plan you and your treating clinician develop together. ATTR-CM therapies, diagnostic testing, and management carry real benefits and real risks that depend on your specific clinical situation, including disease subtype (wild-type vs hereditary), genotype, NYHA functional class, cardiac biomarker stage, comorbidities, and personal goals of care. The critical first step is always confirming the amyloid type — AL (light-chain) and ATTR amyloidosis require completely different treatments, and a mistake can be dangerous. Decisions about starting, continuing, or stopping any medication should be made with a qualified clinician who can review your full history.
Important safety notice. If you experience sudden worsening of breathlessness (especially when lying flat), rapid weight gain (more than 2–3 pounds in a day or 5 pounds in a week), new or worsening leg/ankle swelling, fainting or near-fainting episodes, new dizziness upon standing, chest pain, or a very slow or irregular heartbeat, seek immediate medical attention. ATTR-CM patients are at high risk for dangerous heart rhythm problems and fluid overload. CRITICAL: AL (light-chain) amyloidosis must ALWAYS be excluded before confirming ATTR-CM. Serum free light chains, serum immunofixation, and urine immunofixation are mandatory. Treating AL with TTR stabilizers delays life-saving chemotherapy. Treating ATTR with chemotherapy causes harm. Digoxin is contraindicated in ATTR-CM (binds amyloid fibrils, causing toxicity at therapeutic levels). Beta-blockers may cause dangerous cardiac output reduction in patients with fixed stroke volume. Do not stop or change any ATTR-CM medication without consulting your cardiologist.
Content last reviewed: May 2026 · Based on 2023 ACC Expert Consensus Decision Pathway · 2025 ACC Concise Clinical Guidance (JACC) · 2023 ESC Guidelines on Cardiomyopathies and the 2021 ESC Position Statement on Cardiac Amyloidosis · ATTR-ACT · ATTRibute-CM · HELIOS-B · APOLLO-B · CARDIO-TTRansform · FDA Labels: tafamidis, acoramidis, vutrisiran · Always verify with your medical team.
⚡ Quick Start — If You Read Nothing Else
The 10 most important things to know right now.
ATTR cardiac amyloidosis is treatable, but massively under-diagnosed. Studies suggest 13–16% of elderly patients with heart failure and unexplained thickening of the heart wall actually have ATTR-CM. Many are told they have “hypertensive heart disease” and never get tested. The gap is no longer treatment — it is diagnosis.
The first safety rule: rule out AL amyloidosis. ATTR and AL (light-chain) amyloidosis look similar but require completely different treatments. AL amyloidosis needs chemotherapy; ATTR-CM needs protein stabilizers or gene silencers. Treating the wrong type can be harmful. Blood and urine tests for monoclonal protein are mandatory before any ATTR-CM diagnosis is confirmed.
A nuclear scan can diagnose ATTR-CM without a heart biopsy. A Tc-99m PYP bone scintigraphy scan (or DPD in Europe) with Grade 2–3 uptake, combined with negative monoclonal protein tests, confirms ATTR-CM with greater than 99% accuracy. This transformed a disease that once required cardiac biopsy.
Genetic testing tells you whether your ATTR is inherited or age-related. Wild-type ATTR-CM (wtATTR) affects mostly elderly men and is not inherited. Hereditary ATTR (hATTR) is caused by gene mutations and can affect family members. Knowing which type you have changes treatment, prognosis, and family screening needs.
Tafamidis was the first approved therapy — proven to reduce death by 30%. Available since 2019 as Vyndaqel (80 mg) or Vyndamax (61 mg) taken daily. These are NOT interchangeable by milligram due to different formulations. Works by stabilizing the TTR protein to prevent it from falling apart and forming amyloid deposits.
Acoramidis (Attruby) is a next-generation stabilizer with stronger TTR binding. FDA approved November 2024. Taken as two 356 mg tablets twice daily (712 mg BID). Achieves near-complete TTR stabilization (≥90%), significantly greater than tafamidis. The ATTRibute-CM trial showed a 42% reduction in mortality plus cardiovascular hospitalizations.
Vutrisiran (Amvuttra) is the first gene silencer approved for ATTR-CM. FDA approved March 2025 for ATTR-CM after the HELIOS-B trial. A single subcutaneous injection every 3 months. Works by reducing the liver’s production of the TTR protein by approximately 80–85%. Offers a fundamentally different approach from stabilizers.
Digoxin is dangerous in ATTR-CM — avoid it. Digoxin binds to amyloid fibrils and can reach toxic levels even at “normal” doses. Beta-blockers and calcium channel blockers also require extreme caution because ATTR-CM patients rely on heart rate to maintain cardiac output. SGLT2 inhibitors (like dapagliflozin and empagliflozin) may be helpful for selected patients with heart failure, but ATTR-CM-specific evidence remains limited.
CRISPR gene editing is a potentially curative one-time treatment under investigation. NTLA-2001 (nexiguran ziclumeran) is a single intravenous infusion that edits the TTR gene in liver cells. Phase 1 data showed greater than 90% sustained TTR reduction. The Phase 3 MAGNITUDE trial (~1,200 patients) is enrolling after an FDA clinical hold (due to a serious liver safety event) was lifted in March 2026. Long-term safety and efficacy remain under study.
Early treatment gives the best results. All three approved therapies work best when started before significant heart damage accumulates. If you or your doctor suspects ATTR-CM, getting tested promptly can make a meaningful difference in outcomes. The 2025 ACC guidance recommends starting disease-modifying therapy at the earliest symptomatic stage.
Overview — What Is ATTR Cardiac Amyloidosis?
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a serious heart condition caused by a protein called transthyretin (TTR) that becomes unstable, falls apart, and deposits as amyloid in the heart muscle. This makes the heart wall stiff and thick, eventually leading to heart failure. ATTR-CM has undergone one of the most dramatic treatment transformations in modern cardiology: just a decade ago, it was discovered mainly at autopsy and considered untreatable. Today, it can be diagnosed with a nuclear scan, and three FDA-approved disease-modifying therapies are available, with more in development.
Two Types of ATTR-CM
Wild-type ATTR-CM (wtATTR-CM) — formerly called “senile cardiac amyloidosis.” The TTR protein becomes unstable with aging. It predominantly affects men over age 65–70. It is not inherited and has no gene mutation. Autopsy studies find TTR amyloid deposits in up to 25% of hearts over age 80, though not all develop symptomatic disease.
Hereditary ATTR-CM (hATTR-CM) — caused by inherited mutations in the TTR gene. Over 130 different mutations have been identified. The most important for cardiac disease include:
Val122Ile (V122I) — present in 3–4% of Black/African Americans (~1.5 million carriers in the US). Predominantly causes cardiomyopathy. The most common pathogenic TTR variant in the United States.
Thr60Ala (T60A) — common in people of Irish/British descent. Causes a mixed pattern of cardiomyopathy and neuropathy.
Val30Met (V30M) — endemic in Portugal, Sweden, and Japan. Primarily causes polyneuropathy but can also involve the heart, especially in late-onset cases.
Why Is ATTR-CM Under-Diagnosed?
ATTR-CM is one of the most under-diagnosed conditions in cardiology. Estimates suggest 300,000–500,000 people in the United States have ATTR-CM, but fewer than 15% have been diagnosed. Many patients are told they have “hypertensive heart disease,” “diastolic heart failure,” or “HFpEF” (heart failure with preserved ejection fraction) without anyone checking for amyloid. The PRACTICA study found ATTR-CM in 16.8% of HFpEF patients over age 75 with thickened heart walls.
Red Flags — When Should You or Your Doctor Think About ATTR-CM?
Heart failure with unexplained left ventricular hypertrophy (wall thickness ≥12 mm), especially in men over 65
“Hypertensive heart disease” that does not respond well to standard heart failure treatment
Low-voltage or normal-voltage ECG that seems inconsistent with thick heart walls on echocardiogram
Bilateral carpal tunnel syndrome — often appears 5–10 years before cardiac symptoms
Lumbar spinal stenosis
Biceps tendon rupture
Aortic stenosis (ATTR-CM is present in 8–16% of patients undergoing transcatheter aortic valve replacement)
Atrial fibrillation combined with heart failure and thickened heart walls
Peripheral neuropathy (numbness/tingling in hands and feet), especially with cardiac involvement
Could my heart failure or thickened heart walls be caused by amyloid deposits?
Have you tested my blood and urine to rule out AL (light-chain) amyloidosis?
Should I have a bone scintigraphy scan (Tc-99m PYP) to check for ATTR-CM?
Could my carpal tunnel syndrome or spinal stenosis be related to amyloidosis?
Should I be referred to a center that specializes in cardiac amyloidosis?
Diagnosis & Testing
The diagnostic pathway for ATTR-CM has been revolutionized. Cardiac biopsy is no longer required in most cases. A non-invasive approach using bone scintigraphy plus blood and urine tests to rule out AL amyloidosis can confirm the diagnosis with greater than 99% accuracy.
The Non-Invasive Diagnostic Pathway (Standard of Care)
Clinical suspicion — recognize red flags: HFpEF with unexplained LVH, especially in older adults
Echocardiography — concentric LVH, diastolic dysfunction, characteristic “cherry on top” (apical sparing) strain pattern on speckle tracking
Rule out AL amyloidosis (MANDATORY) — serum free light chains, serum immunofixation, and urine immunofixation. All three tests are needed. If any monoclonal protein is detected, further evaluation (often hematology referral and bone marrow biopsy) is required before proceeding.
Bone scintigraphy — Tc-99m PYP scan (in the US) or Tc-99m DPD (in Europe). This nuclear scan detects ATTR amyloid in the heart.
Grade 0: No cardiac uptake — ATTR-CM unlikely
Grade 1: Mild cardiac uptake, less than bone — indeterminate; may need cardiac biopsy
Grade 2: Cardiac uptake equal to bone — diagnostic of ATTR-CM (with negative monoclonal protein)
Grade 3: Cardiac uptake greater than bone — diagnostic of ATTR-CM (with negative monoclonal protein)
Genetic testing — recommended for all confirmed ATTR-CM patients to distinguish wild-type from hereditary disease. This determines whether family members need screening.
Critical point: When Grade 2–3 bone scintigraphy uptake is present AND monoclonal protein tests are negative, the positive predictive value for ATTR-CM exceeds 99%. No biopsy is needed. This combination is now the gold standard. However, if monoclonal protein is detected (even with Grade 2–3 uptake), cardiac biopsy with Congo red staining and mass spectrometry typing is required because AL amyloidosis can also show uptake on bone scintigraphy.
Additional Diagnostic Tools
Cardiac MRI with late gadolinium enhancement (LGE) and T1 mapping/extracellular volume (ECV) quantification can support the diagnosis. Findings suggestive of amyloid include: diffuse subendocardial or transmural LGE, elevated native T1 values, elevated ECV, and difficulty “nulling” the myocardium. Cardiac MRI cannot reliably distinguish ATTR from AL amyloidosis — bone scintigraphy and monoclonal protein screening are still needed.
Once ATTR-CM is diagnosed, cardiac biomarkers help determine disease stage and prognosis:
NT-proBNP — reflects the degree of heart failure; higher levels indicate more advanced disease
Troponin — indicates ongoing heart muscle damage from amyloid infiltration
The Gillmore staging system uses NT-proBNP (>3,000 pg/mL) and eGFR (<45 mL/min) to classify patients into Stage I, II, or III, with significant differences in median survival
The Mayo (Grogan) staging system uses NT-proBNP (>3,000 pg/mL) and troponin T (≥0.05 ng/mL) thresholds for prognostic stratification
Earlier-stage patients consistently show better outcomes with disease-modifying therapy, reinforcing the importance of early diagnosis.
Bone scintigraphy shows Grade 1 uptake (indeterminate)
Monoclonal protein is detected alongside Grade 2–3 uptake (need to distinguish AL from ATTR)
Bone scintigraphy is negative but clinical suspicion for cardiac amyloidosis remains high (could be AL amyloidosis, which does not reliably light up on PYP scans)
Endomyocardial biopsy with Congo red staining and mass spectrometry typing is the definitive test when needed.
What was my bone scintigraphy Grade (0–3) and heart-to-contralateral ratio?
Have we fully ruled out AL amyloidosis with serum/urine tests? Why does this matter for my treatment?
Should I have genetic testing? What are the implications for me and my family?
Is a cardiac biopsy still needed in my case, or is the non-invasive pathway sufficient?
Where can I get Tc-99m PYP scintigraphy locally (University of Utah or Intermountain)?
What is my cardiac biomarker stage, and what does it mean for my prognosis?
Treatment Options
ATTR-CM treatment has been transformed. As recently as 2018, there were no FDA-approved disease-modifying therapies. Today there are three approved drugs from two distinct mechanistic classes, with more in the pipeline. Treatment works best when started early, before significant heart damage accumulates.
Disease-Modifying Therapies: TTR Stabilizers
TTR stabilizers work by binding to the TTR protein and holding it together, preventing it from falling apart and forming amyloid. They do not remove existing amyloid but slow or stop new deposition.
How it works: Stabilizes the TTR tetramer to prevent dissociation and amyloid formation
Trial evidence: ATTR-ACT trial (441 patients, 30 months) showed 30% reduction in all-cause mortality and 32% reduction in cardiovascular hospitalizations
Dosing: Vyndaqel 80 mg daily (four 20 mg capsules) OR Vyndamax 61 mg daily (single capsule). These are NOT interchangeable per milligram — they are different formulations with different bioavailability
Administration: Oral, once daily
Real-world data (2025): 624 patients across 5 US amyloidosis centers, median follow-up 43 months. Freedom from death at 65 months was 54%, with higher survival compared to untreated patients in the THAOS registry
Cost: Approximately $225,000 per year. Patient assistance programs available through Pfizer
Side effects: Generally well-tolerated. Urinary tract infections and falls reported in trials
How it works: Next-generation TTR stabilizer achieving near-complete stabilization (≥90%), significantly greater than tafamidis, including for the Val122Ile variant
Trial evidence: ATTRibute-CM trial (>600 patients, 30 months). Primary composite endpoint win ratio 1.8 (p<0.0001). 42% reduction in all-cause mortality plus cardiovascular hospitalizations. 50% reduction in hospitalization frequency at 30 months
Long-term data: 54-month open-label extension data (ACC 2026) showed sustained long-term survival benefits. Patients on continuous acoramidis from trial start had significantly better outcomes than those initially on placebo
Preliminary real-world data (medRxiv preprint, April 2026; not yet peer-reviewed): Acoramidis showed significantly lower risk of diuretic intensification events and composite events compared to tafamidis
Cost: Approximately $186,000 per year. Patient assistance through BridgeBio
Key advantage: Only FDA-approved product with label specifying near-complete TTR stabilization. May be particularly beneficial for patients with variants (like Val122Ile) where tafamidis achieves incomplete stabilization
Disease-Modifying Therapies: TTR Gene Silencers
Gene silencers take a fundamentally different approach: instead of stabilizing the TTR protein, they reduce the liver’s production of TTR protein. This cuts off the supply of the misfolding protein at its source.
How it works: RNA interference (RNAi) therapy that silences TTR messenger RNA in the liver, reducing TTR protein production by approximately 80–85%
Trial evidence: HELIOS-B trial (655 patients, 36 months). 28% reduction in composite of all-cause mortality plus recurrent cardiovascular events (overall population). 36% reduction in all-cause mortality. 33% reduction in CV mortality. 46% reduction in urgent HF visits
Extended data (48 months, ESC 2025): 37% risk reduction in composite endpoint (overall population); 42% risk reduction in monotherapy group. 37% reduction in all-cause mortality (overall); 39% in monotherapy group
Dosing: 25 mg subcutaneous injection every 3 months (quarterly)
Administration: Subcutaneous injection, administered by a healthcare provider or trained self-injection. Home administration available
Cost: Approximately $441,000 per year. Patient assistance through Alnylam Assist
Safety: Discontinuation rates and adverse events similar to placebo in trials. Well-tolerated overall
Vitamin A supplementation: Vutrisiran lowers serum TTR, which transports vitamin A. Your doctor will recommend daily vitamin A supplementation while on this therapy
First and only RNAi therapeutic approved for both ATTR-CM and hATTR polyneuropathy
How it works: RNAi therapy that also silences TTR mRNA, similar mechanism to vutrisiran
FDA status: Approved in 2018 for hereditary ATTR polyneuropathy. The APOLLO-B trial in ATTR-CM met its primary endpoint (6-minute walk test improvement at 12 months) but did not show a significant reduction in the secondary composite of mortality and cardiovascular events. The FDA issued a Complete Response Letter in October 2023, declining ATTR-CM approval. It is NOT specifically FDA-approved for ATTR-CM
Dosing: 0.3 mg/kg intravenous infusion every 3 weeks, with premedication (corticosteroids, antihistamines, acetaminophen)
Practical note: The need for IV infusions every 3 weeks with premedication makes this less convenient than vutrisiran’s quarterly subcutaneous injection. Vutrisiran has largely superseded patisiran for ATTR-CM
Should Stabilizers and Gene Silencers Be Combined?
Current evidence (2025 ACC Guidance): Combination of a TTR stabilizer plus a gene silencer is NOT routinely recommended. In the HELIOS-B trial, adding vutrisiran to patients already taking tafamidis did not achieve statistical significance for the primary endpoint. The monotherapy group (vutrisiran without background tafamidis) consistently showed stronger benefits. The CARDIO-TTRansform trial (eplontersen, results expected 2026) enrolled 70% of patients on background tafamidis and may clarify whether combination therapy adds benefit. Until those results are available, the 2025 ACC guidance recommends choosing one approach — stabilizer or silencer — rather than combining them routinely.
Supportive Heart Failure Management
Disease-modifying therapy addresses the underlying amyloid problem. Supportive HF management addresses the symptoms and complications of the damaged heart.
Diuretics (furosemide, bumetanide, torsemide) — essential for managing fluid overload. ATTR-CM patients often need high doses. Daily weight monitoring is critical
SGLT2 inhibitors (dapagliflozin, empagliflozin) — may be helpful for patients with heart failure, kidney disease, or diabetes; ATTR-CM-specific randomized evidence is limited but use is reasonable as part of guideline-directed HF therapy
Anticoagulation for atrial fibrillation — mandatory for all ATTR-CM patients with AF, regardless of CHA2DS2-VASc score. ATTR-CM creates a high-risk prothrombotic state. DOACs (apixaban, rivaroxaban) or warfarin may be used
Amiodarone — preferred rate-control agent for atrial fibrillation in ATTR-CM when digoxin and beta-blockers are problematic
Digoxin — CONTRAINDICATED. Digoxin binds to amyloid fibrils in the heart, concentrating the drug at the tissue level. This causes toxicity even at “therapeutic” blood levels. Do not use digoxin in ATTR-CM.
Beta-blockers — use with extreme caution. ATTR-CM patients have a fixed, reduced stroke volume due to the stiff heart. They rely on heart rate to maintain cardiac output. Slowing the heart rate with beta-blockers can cause dangerous drops in blood pressure and cardiac output. If absolutely needed for AF rate control, start very low and monitor closely
Calcium channel blockers (verapamil, diltiazem) — negative inotropic effects plus potential binding to amyloid fibrils. Generally avoided
ACE inhibitors / ARBs — may cause severe hypotension, especially in patients with autonomic neuropathy (which is common in hereditary ATTR). Use cautiously if at all, at very low doses
Conduction system disease (slow heart rhythms, heart block) is common in ATTR-CM because amyloid infiltrates the heart’s electrical system. Many ATTR-CM patients eventually need a pacemaker. The decision about implantable cardioverter-defibrillators (ICDs) is more nuanced — the primary mode of death in ATTR-CM is often progressive heart failure or electromechanical dissociation rather than ventricular tachycardia, so ICDs may be less effective at preventing sudden death than in other cardiomyopathies. Discuss this carefully with your cardiologist.
Which disease-modifying therapy is best for me — a stabilizer (tafamidis or acoramidis) or a gene silencer (vutrisiran)?
Does my genetic test result affect which drug is likely to work best?
Has my current medication list been reviewed for ATTR-CM safety? Am I taking anything that should be stopped or changed?
Am I a candidate for any clinical trials, including CRISPR gene editing?
What is the cost of the recommended therapy, and what patient assistance programs are available?
Should I be on anticoagulation for my atrial fibrillation, even if my CHA2DS2-VASc score is low?
Do I need a pacemaker? What about an ICD?
Living with ATTR-CM
Managing ATTR-CM is a long-term journey that extends beyond taking medication. Many patients live years and even decades with appropriate treatment and monitoring, especially when diagnosed and treated early.
Monitoring Your Condition
The 2025 ACC guidance recommends regular monitoring every 6–12 months:
NYHA functional class — your doctor’s assessment of how your heart failure affects daily activities
6-Minute Walk Distance (6MWD) — a simple walking test that measures exercise capacity over time
NT-proBNP and troponin — blood tests that track heart stress and damage
ECG and echocardiogram — to monitor heart rhythm, wall thickness, and function
Daily weight — weigh yourself each morning. Report weight gain of more than 2–3 pounds in a day or 5 pounds in a week to your care team
Managing Extracardiac Symptoms
ATTR-CM is not just a heart disease. The TTR protein deposits throughout the body, and many patients experience symptoms beyond the heart:
Bilateral carpal tunnel syndrome is extremely common in ATTR-CM and often appears 5–10 years before cardiac symptoms. Many patients have already had carpal tunnel release surgery before their heart diagnosis. If you had bilateral CTS, especially at a relatively young age, mention this to your cardiologist — it is a red flag for ATTR amyloidosis.
Hereditary ATTR commonly causes peripheral neuropathy (numbness, tingling, pain in hands and feet) and autonomic neuropathy (low blood pressure when standing, dizziness, digestive problems, bladder issues). Treatment may include:
Compression stockings and midodrine or fludrocortisone for orthostatic hypotension
Gabapentin or pregabalin for neuropathic pain
Small, frequent meals for GI dysmotility
Physical therapy for balance and mobility
Gene silencer therapy (vutrisiran) treats both the cardiac and neurologic manifestations of ATTR, which may make it particularly appropriate for patients with mixed disease.
Lumbar spinal stenosis from amyloid deposition in spinal ligaments is common. If you have both spinal stenosis and heart thickening, ATTR amyloidosis should be considered as a unifying diagnosis. Surgical decompression can be performed when symptoms warrant, but the amyloid tissue removed during surgery should be tested for ATTR.
Hereditary ATTR: Family Implications
If you have hereditary ATTR-CM: Each of your children has a 50% chance of inheriting the mutation. Genetic counseling and cascade testing for first-degree relatives (children, siblings) is strongly recommended. Not everyone who inherits the mutation will develop disease (penetrance varies by mutation and age), but knowing their status allows for early monitoring and, when appropriate, early treatment before irreversible damage occurs.
Emotional and Practical Support
Being diagnosed with ATTR-CM can feel overwhelming, especially if your diagnosis was delayed for years. Many patients describe frustration from being told there was “nothing wrong” or receiving incorrect diagnoses. You are not alone. Connecting with other patients through support groups (Amyloidosis Research Consortium, Amyloidosis Support Groups) can be valuable. The treatment landscape has changed dramatically, and most patients now have access to effective therapy.
Learn to recognize signs of heart failure decompensation: weight gain, increased swelling, worsening shortness of breath, especially when lying flat
Help manage multiple specialist appointments (cardiologist, neurologist, geneticist, hematologist)
Support medication adherence for expensive, sometimes complex therapies
Understand the difference between cardiac symptoms (breathlessness, swelling) and neurologic symptoms (numbness, dizziness on standing, digestive issues)
Take care of yourself — caregiver burnout is real. Ask your care team about social work resources
How often should I come in for monitoring, and what tests will you track?
What symptoms should prompt me to call your office or go to the emergency department?
Should my family members be tested for the TTR gene mutation?
Can you refer me to a genetic counselor?
Are there support groups or social work resources you can recommend?
Should I see a neurologist for my neuropathy symptoms?
Pregnancy, Family Planning & Genetic Counseling
There are two forms of ATTR cardiomyopathy. Wild-type ATTR (wtATTR) is age-related, is not inherited, and overwhelmingly affects older adults — so pregnancy is rarely a consideration. Hereditary ATTR (ATTRv) is caused by an inherited TTR gene variant, can appear in younger adults, and carries real family-planning implications.
⚠ If you have hereditary (variant) ATTR, each of your children has a 50% chance of inheriting the gene variant. ATTRv is autosomal dominant. First-degree relatives should be offered genetic counseling and testing (cascade testing), and family planning options — including prenatal and preimplantation genetic testing — can be discussed with a genetic counselor and a reproductive specialist.
Tafamidis (Vyndaqel/Vyndamax): animal studies suggest it may cause fetal harm; it is generally avoided in pregnancy. Discuss contraception with your team if you could become pregnant.
Vutrisiran (Amvuttra) and patisiran: these gene-silencers lower the level of vitamin A in the blood, and vitamin A is essential for a developing baby (both too little and too much can cause harm). The labels advise taking the recommended daily allowance of vitamin A and seeing an eye doctor if vision symptoms develop. Pregnancy decisions with these drugs need careful, individualized counseling.
Acoramidis (Attruby): human pregnancy data are limited; discuss risks and benefits with your team.
General: ATTR-CM during pregnancy is uncommon but, when it occurs, is best managed by a team including cardiology and maternal-fetal medicine.
Questions to ask your team: Do I have the hereditary (variant) or wild-type form? Should my children and siblings be tested? Should I see a genetic counselor before planning a pregnancy? Which of my medicines are safe if I become pregnant, and what should I do about vitamin A?
While disease-modifying therapies significantly slow progression, some patients develop advanced heart failure despite treatment. This is more common when treatment was started late or when the amyloid burden was already substantial at diagnosis. Options for advanced disease include:
Heart transplant can be considered for selected ATTR-CM patients with advanced heart failure:
Wild-type ATTR-CM: Age is often the limiting factor. Outcomes have improved as programs gain experience with amyloidosis patients
Hereditary ATTR-CM: Combined heart-liver transplant may be considered in younger patients. The liver produces TTR, so replacing the liver eliminates the source of mutant protein. Gene silencer therapy is increasingly used as an alternative to liver transplant
Post-transplant, patients with hereditary ATTR typically need gene silencer therapy or TTR stabilization to prevent amyloid deposition in the new heart from circulating variant TTR (if liver was not also replaced)
Clinical Trials and Emerging Therapies
What it is: A single intravenous infusion using CRISPR/Cas9 technology to permanently edit the TTR gene in liver cells, dramatically reducing TTR production
Phase 1 data: Greater than 90% reduction in serum TTR by day 28, with reductions durable to approximately 24 months after a single dose in extended follow-up
Phase 3 (MAGNITUDE trial, NCT06128629): Approximately 1,200 patients (expanded from an original 765-patient target). First patient dosed March 2024. Primary endpoint is a composite of cardiovascular mortality plus recurrent cardiovascular events. An FDA clinical hold was placed in late 2025 after a Grade 4 hepatic adverse event (including one patient death, with complicating comorbidities), then lifted March 2, 2026, with enhanced liver monitoring and revised exclusion criteria (ejection fraction <25%, baseline hepatic abnormalities). The hold has affected the original timelines
Why it matters: If successful, this would be the first potentially curative one-time treatment for ATTR, replacing the need for lifelong daily pills or quarterly injections. It would be the first-ever in vivo CRISPR therapy for a cardiac indication
What it is: An antisense oligonucleotide (ASO) that reduces TTR production. Already FDA-approved for hereditary ATTR polyneuropathy. Monthly subcutaneous injection
CARDIO-TTRansform trial (NCT04136171): 1,432 patients (the largest ATTR-CM trial ever), 70% on background tafamidis. Primary endpoint is cardiovascular mortality plus recurrent cardiovascular events at week 140. FDA Fast Track designation granted
Why it matters: If positive in tafamidis-background patients, this trial would establish the combination therapy paradigm (stabilizer plus silencer). Results expected 2026
Current status: Eplontersen is NOT currently FDA-approved for ATTR-CM — only for hereditary ATTR polyneuropathy
Investigational antibodies designed to directly clear existing amyloid deposits from the heart represent the next frontier. Unlike stabilizers (which prevent new deposits) and gene silencers (which reduce TTR production), these therapies aim to remove amyloid that has already accumulated:
Coramitug (formerly PRX004, Novo Nordisk) — anti-ATTR amyloid depleter antibody now in the Phase 3 CLEOPATTRA trial (FDA Fast Track, 2026)
These amyloid-depleting antibodies are still investigational but could eventually be combined with stabilizers or silencers for a comprehensive approach: stop new production, stabilize what remains, and remove what has already deposited.
Diflunisal is an older NSAID (nonsteroidal anti-inflammatory drug) that happens to stabilize TTR. It is used off-label in some countries where tafamidis is unavailable or unaffordable. It has demonstrated TTR stabilization in studies but has limited cardiac outcome data. Its use requires GI prophylaxis (proton pump inhibitor) and regular renal monitoring, as NSAIDs can affect kidney function and cause fluid retention — problematic in heart failure patients. Diflunisal is not FDA-approved for ATTR-CM and should only be used under specialist supervision.
Am I eligible for any clinical trials, including CRISPR gene editing or antibody therapies?
If my current therapy is not working well enough, what are the options for switching?
Should I be evaluated for cardiac transplantation? What about a combined heart-liver transplant?
When should we talk about palliative care to help manage symptoms and quality of life?
Are there new therapies expected to become available in the next year or two?
Failed & De-Adopted Therapies
Knowing what has been tried and did not work is important. The following therapies were investigated for ATTR-CM or cardiac amyloidosis and were either discontinued, failed in clinical trials, or are no longer recommended.
FAILED This combination was investigated as an amyloid fibril disruptor. Preclinical studies suggested doxycycline could disaggregate amyloid fibrils and TUDCA could prevent further aggregation. However, the randomized controlled trial (NCT03481972) showed no significant benefit in ATTR-CM patients. There was no meaningful improvement in cardiac biomarkers, functional capacity, or clinical outcomes compared to standard care. The combination is no longer actively pursued for ATTR-CM.
FAILED Patisiran is approved for hereditary ATTR polyneuropathy, but its bid for an ATTR-CM indication failed. The APOLLO-B trial met its primary endpoint (6-minute walk distance at 12 months) but did not demonstrate a statistically significant reduction in the secondary composite of mortality and cardiovascular events (p=0.057). The FDA issued a Complete Response Letter in October 2023, declining the ATTR-CM approval. Patisiran remains available for hATTR polyneuropathy but is not approved for cardiac amyloidosis. Its successor, vutrisiran (Amvuttra), achieved ATTR-CM approval via the HELIOS-B trial.
DE-ADOPTED When tafamidis was initially used for ATTR polyneuropathy (approved in Europe as a single 20 mg capsule), some clinicians prescribed this dose for cardiac patients. The ATTR-ACT trial demonstrated that the effective cardiac dose is 80 mg daily (four 20 mg capsules) or the bioequivalent Vyndamax 61 mg single capsule. A single 20 mg capsule provides inadequate TTR stabilization for cardiac disease. This lower dose is no longer considered appropriate for ATTR-CM.
DE-ADOPTED Digoxin was historically used for heart failure and atrial fibrillation rate control. In ATTR-CM, digoxin binds to amyloid fibrils in the myocardium, causing dangerous tissue-level accumulation and toxicity even at “therapeutic” serum levels. It is now contraindicated in all forms of cardiac amyloidosis. This is one of the most important medication safety messages in ATTR-CM care.
FAILED EGCG was studied as a potential TTR stabilizer and amyloid fibril disruptor based on in vitro observations. Small observational studies suggested possible cardiac benefit, but controlled study did not demonstrate significant clinical benefit. Additionally, high-dose green tea extract carries a risk of hepatotoxicity. It is not recommended as a therapy for ATTR-CM.
DE-ADOPTED Standard heart failure guidelines recommend beta-blockers and, in some settings, calcium channel blockers. In ATTR-CM, these agents are now recognized as harmful. Beta-blockers reduce heart rate in patients whose cardiac output depends on maintaining heart rate (because stroke volume is fixed by the stiff, amyloid-infiltrated ventricle), potentially causing dangerous hemodynamic collapse. Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) have negative inotropic effects and may also bind amyloid fibrils. Both drug classes are now avoided or used only with extreme caution under specialist supervision.
WITHDRAWN Liver transplantation was pioneered in Portugal in 1990 as a cure for hereditary ATTR, since the liver produces nearly all circulating TTR. While liver transplant eliminates variant TTR production, wild-type TTR continues to deposit amyloid in the heart after transplant, particularly in older patients and those with significant pre-existing cardiac disease. The availability of effective pharmacotherapy (tafamidis, acoramidis, vutrisiran) and investigational CRISPR gene editing has largely replaced liver-only transplant as a primary strategy. Combined heart-liver transplant remains an option in selected young patients with advanced cardiac disease, but isolated liver transplant for ATTR-CM has been largely superseded by medical therapy.
Support & Resources
Utah & Intermountain West
Location: University of Utah Health + Huntsman Cancer Institute, Salt Lake City
Services: Multidisciplinary team (hematology, cardiology, nephrology, neurology, pulmonology, GI). Comprehensive ATTR-CM diagnosis and management, nuclear cardiology (Tc-99m PYP), cardiac MRI, genetic testing and counseling, clinical trial access
Referral growth: Annual new patient referrals have grown over 200% in recent years, reflecting both improved awareness and its status as a regional center of excellence
Contact: 801-585-0236 (general), 801-213-5723 (new patients)
Email: amyloidosis@hci.utah.edu
Support group: Monthly meetings for patients and caregivers
Bone scintigraphy (Tc-99m PYP): Available at University of Utah and Intermountain Health facilities
Genetic testing: Available through University of Utah Genetics, and commercial labs (Ambry, Invitae)
Endomyocardial biopsy: Available at University of Utah interventional cardiology
Cardiac MRI with T1 mapping/ECV: Available at University of Utah and Intermountain
Tafamidis (Vyndaqel/Vyndamax): Specialty pharmacy distribution. Pfizer CoPay program for eligible commercially insured patients
Acoramidis (Attruby): Available since late 2024. BridgeBio patient support program
Vutrisiran (Amvuttra): Quarterly subcutaneous injection. Specialty pharmacy with home administration option. Alnylam Assist patient support program
Insurance navigation: All three therapies typically require prior authorization. Your amyloidosis center or specialty pharmacy should have experience navigating appeals. Ask for a patient advocate if coverage is denied
National Organizations
Amyloidosis Research Consortium (ARC) — arci.org — patient education, clinical trial matching, research advocacy
Amyloidosis Foundation — amyloidosis.org — patient and caregiver resources, physician directory
Amyloidosis Support Groups (ASG) — online and in-person peer support communities
ClinicalTrials.gov — clinicaltrials.gov — search “ATTR cardiomyopathy” or “transthyretin amyloidosis” for current trials
Val122Ile & Health Equity Resources
The Val122Ile variant and health equity: Val122Ile is present in 3–4% of Black/African Americans, making it the most common pathogenic TTR variant in the United States. Black patients with this variant are disproportionately affected by diagnostic delays, limited access to bone scintigraphy and genetic testing, and underrepresentation in clinical trials. If you are Black and have been diagnosed with heart failure or thickened heart walls, especially before age 65, ask your doctor about ATTR-CM screening. If you carry the Val122Ile mutation, your first-degree relatives should be offered genetic testing.
UK National Amyloidosis Centre (NAC) — Royal Free Hospital, London. The world’s largest amyloidosis center. Pioneered DPD scintigraphy for ATTR diagnosis
Portugal: Nacional screening programs for Val30Met in endemic areas (Póvoa de Varzim). Comprehensive ATTR registries. Pioneered liver transplant for hATTR (1990)
Sweden: Val30Met endemic in northern Sweden (Norrbötten). National ATTR registry with 50+ years of natural history data
Japan: Val30Met cluster in Nagasaki. Early adopter of tafamidis, patisiran, and vutrisiran. Strong post-marketing surveillance programs
THAOS (Transthyretin Amyloidosis Outcomes Survey) — global patient registry tracking ATTR outcomes across countries
“Cardiac amyloidosis is always fatal within a few years.” — No. Disease-modifying therapies have dramatically improved survival. Many patients now live years to decades with appropriate treatment, especially when started early.
“You need a heart biopsy to diagnose ATTR-CM.” — No. The non-invasive pathway (bone scintigraphy + AL exclusion) is now the standard of care and is diagnostic in most cases.
“Only old people get ATTR-CM.” — Wild-type ATTR-CM predominantly affects older adults, but hereditary forms (especially Val122Ile) can cause subclinical cardiac changes starting in midlife, well before age 65.
“Tafamidis is the only option.” — There are now three FDA-approved drugs (tafamidis, acoramidis, vutrisiran) plus two Phase 3 agents (eplontersen, NTLA-2001 CRISPR). The therapeutic landscape expanded dramatically in 2024–2025.
“Stabilizers and gene silencers should always be combined.” — Not supported by current evidence. The HELIOS-B trial showed that adding vutrisiran to tafamidis did not reach significance. This may change with CARDIO-TTRansform results.
“ATTR-CM is extremely rare.” — It is massively under-diagnosed. Estimated US prevalence is 300,000–500,000 patients, fewer than 15% diagnosed.
International & Endemic Hereditary ATTR
Japan — earliest tafamidis approval (2013): Tafamidis was first approved in Japan in 2013 for ATTR familial amyloid polyneuropathy (ATTR-FAP), among the earliest approvals worldwide — six years before the US FDA approved it for ATTR-CM in 2019. Japan has long been at the forefront of ATTR research due to endemic Val30Met clusters in Nagano and Kumamoto prefectures.
European diagnostic standard — DPD/HMDP scintigraphy: In Europe, Tc-99m DPD (3,3-diphosphono-1,2-propanodicarboxylic acid) or Tc-99m HMDP scintigraphy is the standard for non-invasive ATTR-CM diagnosis, graded using the Perugini system (Grades 0–3). In the United States, Tc-99m PYP (pyrophosphate) is the equivalent tracer. Both detect ATTR amyloid in the heart with high sensitivity, but the tracers are not interchangeable across regions.
Hereditary ATTR was first described as a clinical entity in certain geographic clusters where founder mutations are concentrated. These endemic foci have driven much of the world’s understanding of the disease:
Portugal (Póvoa de Varzim) — where the disease was first described by neurologist Corino de Andrade in 1952. The Val30Met mutation is endemic here. Portugal pioneered liver transplantation for hATTR in 1990 and maintains comprehensive national screening programs.
Sweden (northern Sweden / Norrbötten) — a large Val30Met cluster, with a national ATTR registry spanning over 50 years of natural history data. Late-onset cases in Sweden often present with more cardiac involvement than early-onset Portuguese cases.
Japan (Nagano / Kumamoto) — Val30Met clusters with extensive clinical research infrastructure. Japan was the first country to approve tafamidis (2013) and has strong post-marketing surveillance programs.
Cyprus — an endemic focus with a high prevalence of hATTR relative to population size.
Majorca (Spain) — an endemic focus in the Balearic Islands with established clinical follow-up programs.
Brazil — Val30Met cases traced to Portuguese ancestry. Growing clinical and registry infrastructure for ATTR diagnosis and management.
Tafamidis (Vyndaqel): EMA approved for ATTR-CM; widely available across Europe, Japan, and other markets
Acoramidis (Attruby / Beyonttra): Approved in the EU as Beyonttra, commercialized by Bayer, since February 2025; also under review/approved in additional markets
Vutrisiran (Amvuttra): EMA approved for both hATTR polyneuropathy and ATTR-CM
Patisiran (Onpattro): EMA approved for hATTR polyneuropathy. Not approved for ATTR-CM in any jurisdiction
Specialty Amyloidosis Center Directory
How to choose the right care setting:
Academic amyloidosis center — Best for initial diagnosis confirmation, complex cases (mixed AL/ATTR workup, hereditary ATTR with neuropathy), clinical trial access, transplant evaluation, and Val122Ile genetic counseling. Seek an academic center if your local cardiologist is unfamiliar with ATTR-CM or if your case involves diagnostic uncertainty.
Community cardiology — Appropriate for ongoing monitoring (echocardiograms, biomarker checks, medication management) once diagnosis is confirmed and a treatment plan is established at an amyloidosis center. Many community cardiologists now have experience managing ATTR-CM patients in collaboration with a specialist center.
VA Medical Center — Veterans with ATTR-CM can receive care through the VA system, which provides cardiology, genetic testing referrals, and specialty pharmacy access at no or reduced cost. The VA can coordinate with academic amyloidosis centers for complex cases.
University of Utah Health — Cardiac Amyloidosis Program: Multidisciplinary amyloidosis team including cardiology, hematology, neurology, nephrology, and genetic counseling. Tc-99m PYP scintigraphy, cardiac MRI, endomyocardial biopsy, genetic testing, and clinical trial access. Salt Lake City, UT. Phone: 801-585-0236 (general), 801-213-5723 (new patients). University of Utah Health main line: 801-581-2121. Email: amyloidosis@hci.utah.edu
Intermountain Health — Cardiology: Advanced cardiac imaging including echocardiography with strain and nuclear cardiology. Referral pathway to University of Utah for confirmed or suspected amyloidosis cases. Multiple locations across Utah and the Intermountain West. Phone: 801-442-2000
George E. Wahlen VA Medical Center: Salt Lake City, UT. Cardiology services for veterans, including heart failure management, echocardiography, and referral pathways to the University of Utah Amyloidosis Program for specialized ATTR-CM care. Phone: 801-582-1565
VA Boston Healthcare System: Boston, MA. Collaboration with Brigham and Women’s Hospital cardiac amyloidosis program for veteran referrals. Phone: 857-203-6000
VA Greater Los Angeles Healthcare System: Los Angeles, CA. Cardiology and heart failure services with referral pathways to UCLA and Cedars-Sinai amyloidosis programs. Phone: 310-478-3711
Veterans at any VA facility can request referral to an academic amyloidosis center through VA Community Care if specialized ATTR-CM expertise is not available locally
Columbia University Amyloidosis Center — New York, NY. One of the largest amyloidosis programs in the US. Comprehensive ATTR-CM and AL amyloidosis diagnosis, treatment, and clinical trials. Phone: 212-305-9770
Stanford Amyloid Center — Stanford, CA. Multidisciplinary team with expertise in advanced cardiac imaging, genetic testing, and novel therapeutics including CRISPR trials. Phone: 650-498-6000
Mayo Clinic — Amyloidosis Program — Rochester, MN (also Scottsdale, AZ and Jacksonville, FL). Internationally recognized amyloidosis expertise. Pioneered cardiac biomarker staging systems. Extensive clinical trial portfolio. Phone: 507-284-2511 (Rochester)
Brigham and Women’s Hospital — Cardiac Amyloidosis Program — Boston, MA. Leaders in ATTR-CM research, non-invasive diagnostics, and novel therapeutics. Key site for ATTR-ACT, ATTRibute-CM, HELIOS-B, and other landmark trials. Phone: 617-732-5500
Toronto General Hospital — Cardiac Amyloidosis Clinic: University Health Network, Toronto, ON. Specialized multidisciplinary clinic for ATTR-CM and AL amyloidosis. Advanced imaging, genetic testing, and clinical trial access. One of Canada’s leading amyloidosis referral centers. Phone: 416-340-4800
McGill University Health Centre — Amyloidosis Program: Montreal, QC. Multidisciplinary amyloidosis care including cardiac and neurologic ATTR. Phone: 514-934-1934
University of British Columbia — Heart Function Clinic: St. Paul’s Hospital, Vancouver, BC. Cardiac amyloidosis diagnosis and management, including bone scintigraphy and genetic testing referrals. Phone: 604-682-2344
Ottawa Heart Institute: Ottawa, ON. Advanced heart failure and cardiac amyloidosis care. Phone: 613-761-5000
UK National Amyloidosis Centre (NAC) — Royal Free Hospital, London: The world’s largest amyloidosis center. Pioneered DPD scintigraphy and the Perugini grading system for non-invasive ATTR-CM diagnosis. Treats patients from across the UK and internationally. Phone: +44 20 7433 2727
University of Pavia — Amyloidosis Research and Treatment Center, Pavia, Italy: A leading European center with decades of experience in cardiac amyloidosis diagnosis and management. Major contributor to ATTR-CM clinical trial data. Phone: +39 0382 502994
Heidelberg University Hospital — Amyloidosis Center, Heidelberg, Germany: Comprehensive amyloidosis program with advanced cardiac imaging, genetic testing, and access to novel therapeutics. Phone: +49 6221 56-0
Kumamoto University Hospital, Kumamoto, Japan: Located within one of Japan’s endemic hATTR foci. Extensive experience with Val30Met ATTR and pioneering work in tafamidis clinical development. Phone: +81 96 344 2111
Clinical Trials
MAGNITUDE (NTLA-2001 / nexiguran ziclumeran): Phase 3, ~1,200 patients. CRISPR/Cas9 gene editing — single IV infusion. Primary endpoint: CV mortality + recurrent CV events. Enrollment resumed March 2026 after FDA clinical hold was lifted. Sponsor: Intellia Therapeutics. NCT06128629
Coramitug (formerly PRX004): Anti-ATTR amyloid depleter antibody; FDA Fast Track (2026) and now in the Phase 3 CLEOPATTRA trial (~1,280 patients). Sponsor: Novo Nordisk / Prothena. NCT07207811
ClinicalTrials.gov: Go to clinicaltrials.gov and search for “ATTR cardiomyopathy” or “transthyretin amyloid cardiomyopathy.” Filter by “Recruiting” status and your geographic location. Results show trial descriptions, eligibility criteria, and contact information for enrolling sites.
Amyloidosis Research Consortium (ARC): Visit arci.org for curated trial listings and a trial matching service. ARC can help identify trials you may be eligible for and facilitate connections with enrolling centers.
Your amyloidosis center: Specialty centers maintain awareness of open trials and can screen you for eligibility. Ask your cardiologist or amyloidosis specialist at every visit whether new trials have opened.
Manufacturer patient support programs: Intellia (NTLA-2001), Ionis/AstraZeneca (eplontersen), and AstraZeneca/Alexion (cliramitug) all have clinical trial information on their corporate websites.
Tip: Clinical trial eligibility criteria can be specific. Do not assume you are ineligible without checking. Many trials accept patients already on tafamidis or acoramidis. Discuss trial participation with your amyloidosis specialist, who can review your full clinical picture against trial criteria.
Glossary
TTR (Transthyretin): A protein made primarily by the liver that carries thyroid hormone and vitamin A in the blood. In ATTR amyloidosis, TTR becomes unstable, misfolds, and deposits as amyloid fibrils in tissues including the heart and nerves.
wtATTR (Wild-type ATTR): ATTR amyloidosis caused by normal (non-mutated) TTR protein that becomes unstable with aging. Formerly called “senile cardiac amyloidosis.” Predominantly affects men over age 65–70. Not inherited.
hATTR (Hereditary ATTR): ATTR amyloidosis caused by an inherited mutation in the TTR gene. Autosomal dominant — each child of a carrier has a 50% chance of inheriting the mutation. Over 130 pathogenic mutations identified.
V122I (Val122Ile): The most common pathogenic TTR mutation in the United States, carried by 3–4% of Black/African Americans (~1.5 million carriers). Predominantly causes cardiomyopathy. Associated with significant health equity concerns due to under-diagnosis in affected communities.
V30M (Val30Met): The most studied TTR mutation globally. Endemic in Portugal, Sweden, Japan, and Brazil. Primarily causes polyneuropathy, but late-onset cases often have significant cardiac involvement.
T60A (Thr60Ala): A TTR mutation common in people of Irish and British descent. Causes a mixed pattern of cardiomyopathy and neuropathy.
Perugini Grade (0–3): A visual grading system for bone scintigraphy (DPD/HMDP/PYP) that quantifies cardiac tracer uptake relative to bone uptake. Grade 0 = no cardiac uptake; Grade 1 = mild (less than bone); Grade 2 = equal to bone; Grade 3 = greater than bone. Grades 2–3 with negative monoclonal protein screening confirm ATTR-CM non-invasively.
PYP Scintigraphy (Tc-99m Pyrophosphate): The bone tracer scan used in the United States for non-invasive ATTR-CM diagnosis. The radiotracer binds to ATTR amyloid deposits in the heart.
DPD Scintigraphy (Tc-99m DPD): The bone tracer scan used in Europe for non-invasive ATTR-CM diagnosis. Functionally equivalent to PYP but uses a different radiotracer (3,3-diphosphono-1,2-propanodicarboxylic acid).
Free Light Chains (FLC): Immunoglobulin light chain fragments measured in blood (serum free light chains) to screen for AL (light-chain) amyloidosis. Abnormal free light chain ratio suggests a plasma cell disorder. This test is mandatory before confirming ATTR-CM to rule out the more dangerous AL type.
HFpEF (Heart Failure with Preserved Ejection Fraction): Heart failure in which the heart pumps normally (ejection fraction ≥50%) but fills abnormally due to stiff, thickened walls. ATTR-CM is a major under-recognized cause of HFpEF, especially in older adults. Studies suggest 13–17% of HFpEF patients with thickened walls may have undiagnosed ATTR-CM.
Apical Sparing: A distinctive pattern seen on speckle-tracking echocardiography (global longitudinal strain) where the base and mid-segments of the heart show reduced function but the apex is relatively preserved. This “cherry on top” or “bulls-eye” pattern is highly suggestive of cardiac amyloidosis and helps distinguish it from other causes of thickened heart walls.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats): A gene-editing technology that can precisely cut and modify DNA sequences. In the context of ATTR-CM, CRISPR/Cas9 (used in NTLA-2001 / nexiguran ziclumeran) targets the TTR gene in liver cells to permanently reduce TTR protein production with a single infusion, potentially offering a one-time cure rather than lifelong therapy.
Important Safety Information for ATTR-CM Treatments
Transthyretin amyloid cardiomyopathy (ATTR-CM) is treated with stabilizers (tafamidis, acoramidis), silencers (patisiran, vutrisiran, eplontersen), and heart failure management. Each class has important safety considerations.
Vyndaqel and Vyndamax are NOT interchangeable: Vyndaqel comes as 20 mg soft gel capsules (prescribed as 4 capsules = 80 mg/day) while Vyndamax is a single 61 mg soft gel capsule (1 capsule/day). These two formulations have different bioavailability profiles and cannot be substituted one for the other. Do not switch formulations without your cardiologist's guidance. Pharmacy substitutions can result in underdosing or overdosing.
There is no currently established Boxed Warning for tafamidis, but monitor for liver enzyme elevations periodically, as hepatic effects have been reported in post-marketing surveillance. Report unusual fatigue, jaundice, or abdominal discomfort.
NSAIDs including diflunisal — Caution in heart failure:
Diflunisal (an NSAID) is sometimes used off-label to stabilize transthyretin in hereditary ATTR (hATTR). However, all NSAIDs — including diflunisal — carry significant risks in patients with heart failure: they cause sodium and fluid retention, worsening heart failure symptoms, and can precipitate acute decompensation. NSAIDs also increase the risk of gastrointestinal bleeding and kidney injury.
If you have established ATTR cardiomyopathy with significant heart failure, discuss with your cardiologist before taking any NSAID (including over-the-counter ibuprofen, naproxen, and aspirin at anti-inflammatory doses).
Heart failure medication precautions specific to ATTR-CM:
Digoxin (Lanoxin): Patients with ATTR-CM amyloid infiltration of the myocardium have increased sensitivity to digoxin toxicity, even at standard doses. Digoxin should be used with extreme caution or avoided; if used, doses are generally lower than usual and blood levels monitored closely.
Calcium channel blockers (verapamil, diltiazem): These are generally avoided in ATTR-CM with heart failure. They can worsen contractile dysfunction due to their negative inotropic effects in an already stiff, non-compliant ventricle.
Diuretics — avoid over-diuresis: ATTR-CM patients with restrictive physiology are preload-dependent (need adequate fluid to fill the stiff ventricle). Aggressive diuresis can cause severe hypotension. Work with your heart failure team to find the right balance — this often requires careful monitoring of daily weights and symptoms.
Atrial fibrillation and anticoagulation: Atrial fibrillation is common in ATTR-CM and carries a very high risk of stroke due to atrial dysfunction even when not strictly in "AF" at the time. Anticoagulation with a DOAC (apixaban, rivaroxaban) or warfarin is typically recommended. Discuss the risks and benefits with your electrophysiologist and heart failure team.